JPMorgan Chase & Co. Reduces Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)

JPMorgan Chase & Co. trimmed its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 17.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 219,568 shares of the biopharmaceutical company’s stock after selling 47,311 shares during the period. JPMorgan Chase & Co. owned 0.45% of Theravance Biopharma worth $2,066,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in the business. KLP Kapitalforvaltning AS purchased a new stake in Theravance Biopharma during the fourth quarter worth approximately $69,000. Teacher Retirement System of Texas purchased a new stake in shares of Theravance Biopharma during the 4th quarter worth approximately $103,000. SG Americas Securities LLC boosted its holdings in shares of Theravance Biopharma by 21.1% in the 4th quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 3,349 shares in the last quarter. Magnetar Financial LLC grew its position in shares of Theravance Biopharma by 125.8% in the 4th quarter. Magnetar Financial LLC now owns 27,511 shares of the biopharmaceutical company’s stock valued at $259,000 after buying an additional 15,328 shares during the last quarter. Finally, Barclays PLC grew its position in shares of Theravance Biopharma by 279.9% in the 3rd quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company’s stock valued at $529,000 after buying an additional 48,316 shares during the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $11.33.

Theravance Biopharma Trading Up 1.0 %

Shares of TBPH opened at $9.54 on Friday. The company’s 50 day simple moving average is $9.09 and its 200-day simple moving average is $9.18. The firm has a market cap of $477.01 million, a PE ratio of -9.45 and a beta of 0.14. Theravance Biopharma, Inc. has a 12-month low of $7.44 and a 12-month high of $10.90.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.26). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The business had revenue of $18.75 million for the quarter, compared to analysts’ expectations of $29.90 million. As a group, equities research analysts forecast that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 370,038 shares of the company’s stock, valued at approximately $3,330,342. This trade represents a 1.07 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 6.90% of the company’s stock.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.